vs
Side-by-side financial comparison of Incyte (INCY) and SCANSOURCE, INC. (SCSC). Click either name above to swap in a different company.
Incyte is the larger business by last-quarter revenue ($1.3B vs $766.5M, roughly 1.7× SCANSOURCE, INC.). Incyte runs the higher net margin — 23.8% vs 2.2%, a 21.7% gap on every dollar of revenue. On growth, Incyte posted the faster year-over-year revenue change (20.9% vs 2.5%). Over the past eight quarters, Incyte's revenue compounded faster (10.4% CAGR vs 0.9%).
Incyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware. The company currently operates manufacturing and R&D locations in North America, Europe, and Asia.
ScanSource, Inc. is a leading global specialty technology distributor offering a broad portfolio of solutions including point-of-sale systems, barcode scanning tools, cybersecurity products, cloud services and communication solutions. It primarily serves value-added resellers, managed service providers and enterprise clients across North America, Latin America and Europe, covering retail, healthcare, industrial and public sector core segments.
INCY vs SCSC — Head-to-Head
Income Statement — Q1 FY2026 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.3B | $766.5M |
| Net Profit | $303.3M | $16.5M |
| Gross Margin | — | 13.4% |
| Operating Margin | 23.7% | 2.3% |
| Net Margin | 23.8% | 2.2% |
| Revenue YoY | 20.9% | 2.5% |
| Net Profit YoY | 91.7% | -3.3% |
| EPS (diluted) | $1.47 | $0.75 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.5B | $766.5M | ||
| Q3 25 | $1.4B | $739.6M | ||
| Q2 25 | $1.2B | $812.9M | ||
| Q1 25 | $1.1B | $704.8M | ||
| Q4 24 | $1.2B | $747.5M | ||
| Q3 24 | $1.1B | $775.6M | ||
| Q2 24 | $1.0B | $746.1M |
| Q1 26 | $303.3M | — | ||
| Q4 25 | $299.3M | $16.5M | ||
| Q3 25 | $424.2M | $19.9M | ||
| Q2 25 | $405.0M | $20.1M | ||
| Q1 25 | $158.2M | $17.4M | ||
| Q4 24 | $201.2M | $17.1M | ||
| Q3 24 | $106.5M | $17.0M | ||
| Q2 24 | $-444.6M | $16.1M |
| Q1 26 | — | — | ||
| Q4 25 | 92.0% | 13.4% | ||
| Q3 25 | 92.8% | 14.5% | ||
| Q2 25 | 93.5% | 12.9% | ||
| Q1 25 | 93.0% | 14.2% | ||
| Q4 24 | 92.5% | 13.6% | ||
| Q3 24 | 92.4% | 13.1% | ||
| Q2 24 | 92.7% | 13.0% |
| Q1 26 | 23.7% | — | ||
| Q4 25 | 22.3% | 2.3% | ||
| Q3 25 | 32.5% | 3.5% | ||
| Q2 25 | 43.6% | 3.3% | ||
| Q1 25 | 19.5% | 3.2% | ||
| Q4 24 | 25.6% | 2.5% | ||
| Q3 24 | 12.8% | 2.3% | ||
| Q2 24 | -45.8% | 2.9% |
| Q1 26 | 23.8% | — | ||
| Q4 25 | 19.9% | 2.2% | ||
| Q3 25 | 31.1% | 2.7% | ||
| Q2 25 | 33.3% | 2.5% | ||
| Q1 25 | 15.0% | 2.5% | ||
| Q4 24 | 17.1% | 2.3% | ||
| Q3 24 | 9.4% | 2.2% | ||
| Q2 24 | -42.6% | 2.2% |
| Q1 26 | $1.47 | — | ||
| Q4 25 | $1.46 | $0.75 | ||
| Q3 25 | $2.11 | $0.89 | ||
| Q2 25 | $2.04 | $0.87 | ||
| Q1 25 | $0.80 | $0.74 | ||
| Q4 24 | $0.90 | $0.70 | ||
| Q3 24 | $0.54 | $0.69 | ||
| Q2 24 | $-2.04 | $0.66 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $83.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $5.6B | $910.9M |
| Total Assets | $7.3B | $1.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $3.1B | $83.5M | ||
| Q3 25 | $2.5B | $124.9M | ||
| Q2 25 | $2.0B | $126.2M | ||
| Q1 25 | $1.9B | $146.3M | ||
| Q4 24 | $1.7B | $110.5M | ||
| Q3 24 | $1.3B | $145.0M | ||
| Q2 24 | $987.3M | $185.5M |
| Q1 26 | $5.6B | — | ||
| Q4 25 | $5.2B | $910.9M | ||
| Q3 25 | $4.7B | $914.0M | ||
| Q2 25 | $4.2B | $906.4M | ||
| Q1 25 | $3.7B | $901.7M | ||
| Q4 24 | $3.4B | $900.7M | ||
| Q3 24 | $3.2B | $920.9M | ||
| Q2 24 | $3.0B | $924.3M |
| Q1 26 | $7.3B | — | ||
| Q4 25 | $7.0B | $1.7B | ||
| Q3 25 | $6.3B | $1.7B | ||
| Q2 25 | $5.8B | $1.8B | ||
| Q1 25 | $5.7B | $1.7B | ||
| Q4 24 | $5.4B | $1.7B | ||
| Q3 24 | $5.0B | $1.8B | ||
| Q2 24 | $4.7B | $1.8B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $30.8M |
| Free Cash FlowOCF − Capex | — | $28.9M |
| FCF MarginFCF / Revenue | — | 3.8% |
| Capex IntensityCapex / Revenue | — | 0.3% |
| Cash ConversionOCF / Net Profit | — | 1.87× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $543.3M | $30.8M | ||
| Q3 25 | $559.4M | $23.2M | ||
| Q2 25 | $44.7M | — | ||
| Q1 25 | $266.1M | $66.1M | ||
| Q4 24 | $381.2M | $-6.2M | ||
| Q3 24 | $310.9M | $44.8M | ||
| Q2 24 | $-575.6M | — |
| Q1 26 | — | — | ||
| Q4 25 | — | $28.9M | ||
| Q3 25 | — | $20.8M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $64.6M | ||
| Q4 24 | — | $-8.2M | ||
| Q3 24 | — | $42.5M | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 3.8% | ||
| Q3 25 | — | 2.8% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 9.2% | ||
| Q4 24 | — | -1.1% | ||
| Q3 24 | — | 5.5% | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.3% | ||
| Q3 25 | — | 0.3% | ||
| Q2 25 | — | 0.3% | ||
| Q1 25 | — | 0.2% | ||
| Q4 24 | — | 0.3% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | — | 0.2% |
| Q1 26 | — | — | ||
| Q4 25 | 1.82× | 1.87× | ||
| Q3 25 | 1.32× | 1.17× | ||
| Q2 25 | 0.11× | — | ||
| Q1 25 | 1.68× | 3.79× | ||
| Q4 24 | 1.89× | -0.36× | ||
| Q3 24 | 2.92× | 2.64× | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
INCY
Segment breakdown not available.
SCSC
| Products And Services | $723.4M | 94% |
| Intelisys Advisory | $25.0M | 3% |
| Recurring Revenue | $18.2M | 2% |
